Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 6/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.65 |
| ▸ | GAA | P10253 | 3/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 8/20 | 0.60 |
| ▸ | HPGD | P15428 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.59 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.58 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3399281 | 0.87 | ALDH1A1 (0.83) | ALDH1A1HTTMEN1KMT2AGAA | |
| SCHEMBL4296039 | 0.85 | ALDH1A1 (0.69) | ALDH1A1HTTMEN1KMT2AGAA | |
| SCHEMBL3404785 | 0.83 | ALDH1A1 (0.66) | ALDH1A1HTTMEN1KMT2AGAA | |
| SCHEMBL3429016 | 0.83 | NR1H4 (0.59) | ALDH1A1HTTSMN1; SMN2MAPTHPGD | |
| SCHEMBL4304963 | 0.82 | ALDH1A1 (0.68) | ALDH1A1HTTMEN1KMT2AGAA | |
| SCHEMBL3399313 | 0.82 | ALDH1A1 (0.68) | ALDH1A1HTTMEN1KMT2AGAA | |
| SCHEMBL3402004 | 0.82 | MAPT (0.69) | ALDH1A1HTTMEN1KMT2AGAA | |
| SCHEMBL3399874 | 0.79 | ALDH1A1 (1.00) | ALDH1A1HTTMEN1KMT2AGAA | |
| SCHEMBL3401577 | 0.79 | NR1H4 (0.59) | ALDH1A1SMN1; SMN2MAPTHPGDPOLB | |
| SCHEMBL3401013 | 0.78 | ALDH1A1 (0.69) | ALDH1A1HTTMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101990537-A | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBOTT LAB | 2011-03-23 | — | — | CN | claimed |
| EP-2250162-A2 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2010-11-17 | — | — | EP | claimed |
| US-20090270408-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-10-29 | — | — | US | claimed |
| WO-2009100294-A2 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | WO | claimed |
| EP-2250162-B1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-03-19 | — | — | EP | disclosed |
| US-8536221-B2 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBVIE INC. (US) | 2013-09-17 | — | — | US | disclosed |
| CN-101990537-A | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBOTT LAB | 2011-03-23 | — | — | CN | disclosed |
| EP-2250162-A2 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20090270408-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2009100294-A2 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270408-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | CHRNA2, CHRNA4, CHRNA5 | ALDH1A1 4282/4885HTT 1768/4885MEN1 4147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.